New combo attack on breast cancer brain metastases: immunotherapy plus chemo and radiation
NCT ID NCT06839560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a PD-L1 antibody (adebrelimab) to a three-drug chemotherapy regimen (vinorelbine, cyclophosphamide, capecitabine) and either early or delayed radiotherapy can help control brain tumors in people with advanced HER2-negative breast cancer. About 102 participants will be randomly assigned to receive the combination with concurrent or delayed radiation. The main goal is to see how long the brain tumors stay under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adebrelimab (PD-L1 monoclonal antibody) plus vinorelbine, cyclophosphamide, and capecitabine (VEX metronomic chemotherapy) with radiotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for people with HER2-negative breast cancer that has spread to the brain, potentially improving control of brain tumors.
- What could go wrong
- This is an early-phase study with only 102 participants, so results may not apply to everyone. The combination of drugs and radiation may cause significant side effects, and it is not yet known if it works better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS FROM ADVANCED HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing 100021
RECRUITINGBeijing, Beijing Municipality, 100021, China